The newest venture from Mount Sinai is intended to build a pipeline of physician-scientists.
This week, Mount Sinai Health System and Icahn School of Medicine announced the launch of the Institute for Airway Sciences (IAS), a multidisciplinary institute intended to establish new therapies for patients with sinus, laryngotracheal airway, and lung diseases.
The institute is the first clinical and research collaborative of its kind in the US.
Under the guidance of Eric Genden, MD, MBA, Professor and System Chair of Otalaryngology, along with several clinical directors at Mount Sinai including Dr. Isidore Friesner and Dr. Charles Powell, the Institute for Airway Sciences will bring together a multidisciplinary group of researchers and clinicians to establish new goals for conquering airway diseases.
The institute will aid in the promotion of research and innovation of 4 resource cores including the Black Family Stem Cell Institute, the Department of Cell, Developmental and Regenerative Biology, the Division of Pulmonary, Critical Care and Sleep Medicine, and the Department of Otolaryngology – Head and Neck Surgery.
To encourage innovative projects from medical students and residents in training as well as to build a pipeline of physician-scientists, the IAS will award pilot grants and user scholarships in addition to offering seminars and research-in-progress talks focused on airway science and various diseases that affect the airway.
“We wanted to develop a clinical and research hub solely dedicated to the airway—from the sinuses all the way down to the lungs,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System. “The researchers and clinicians involved in this collaboration bring profound expertise and talent in their respective areas and we look forward to bringing the Institute’s mission and vision to life.”